E3 Ubiquitin Protein Ligase Mdm2 Pipeline Review Market H2 2016 E3 Ubiquitin Protein Ligase Mdm2 Market 2016 | Page 9

R&D Progress 61
Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53
Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Dormant Projects 64
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53
Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Discontinued Products 67
Read Complete Report With TOC @ http://www.radiantinsights.com/research/e3-ubiquitinprotein-ligase-mdm2
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53
Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Featured News & Press Releases 68
Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced
Hematologic and Solid Malignancies with Wild Type p53 68
Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH 69
Aug 15, 2013: Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53
Pathway Re-activator for the Treatment of Solid and Hematologic Cancers 69
Nov 07, 2012: Aileron Therapeutics Presents New Data On Stapled Peptide Oncology Program At
EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 70
Oct 31, 2012: Aileron Therapeutics To Present Data On Stapled Peptides At Upcoming Scientific
Conferences And Industry Events 71
Appendix 72
Methodology 72